hyphens pharma
Hyphens Pharma bets big on Asean’s medical aesthetics boom
While the group is not exposed to tariff pressures, currency volatility remains a near-term challenge
Strong corporate governance is key as companies navigate uncertain times
BOARDS of directors play a key role in ensuring transparency, accountability, performance orientation, good processes and practices in companies.
Hyphens Pharma to expand footprint in South-east Asia: CEO
SINGAPORE’S leading specialty pharmaceutical and consumer healthcare group, Hyphens Pharma International, is expanding its South-east Asia footprint beyond the five countries that it is already in, sa...
Hyphens Pharma to sell 10% stake in digital healthtech unit to Metro for S$6m
CATALIST-LISTED Hyphens Pharma International on Friday (May 27) said property and retail company Metro Holdings has agreed to invest S$6 million for a 10 per cent stake in the former’s digital healtht...
Brokers' take: CGS-CIMB initiates 'add' on Hyphens Pharma with S$0.36 target price
CGS-CIMB on Friday (Jan 7) initiated coverage on Hyphens Pharma with an "add" call and target price of S$0.36. The research team believes the pharmaceutical and consumer healthcare company's share pri...
Hyphens Pharma inks exclusive licensing deal with Favorex to commercialise biosimilar in Singapore, Malaysia, Philippines
CATALIST-LISTED Hyphens Pharma has inked an exclusive licensing deal to commercialise an antibody biosimilar drug in Singapore, Malaysia, and the Philippines, in order to expand their dermatology prod...
Hyphens Pharma to acquire Novem companies for S$16.3 million
CATALIST-LISTED Hyphens Pharma will acquire Novem Healthcare, Novem Pharma and Novem Sciences (Novem companies) for S$16.3 million to augment its current healthcare products and services.
Brokers' take: KGI upgrades Hyphens Pharma to 'outperform' after Q1 comeback
KGI Securities has upgraded its call on Catalist-listed Hyphens Pharma from "neutral" to "outperform" with a higher target price of S$0.43 compared to S$0.36 previously, upon rolling forward estimates...
Hyphens Pharma to expand presence in South Korea through distribution agreement with JSPharma
HYPHENS Pharma International is planning to cement its regional presence by appointing dermo-cosmetic products and medical devices distributor and promoter JSPharma as an exclusive distributor of its ...
Hyphens Pharma books provision for unsold Covid-19 test kits; Q3 profit halves
HYPHENS Pharma International's net profit shrank by 53 per cent to S$847,000 for the third quarter, from S$1.8 million a year ago.
